-
Sector Analysis
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC) – Market Drivers and Challenges
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients. - Targeted therapy in NSCLC is a highly competitive...
-
Product Insights
Squamous Non-Small Cell Lung Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer - Global Clinical Trials Review, 2025" provides an overview of Squamous Non-Small Cell Lung Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Squamous Non-Small Cell Lung Cancer - Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma is a subtype of non-small cell lung cancer (NSCLC) originating in the squamous cells lining the airways. It constitutes about 25-30% of all lung cancers. Linked to smoking, symptoms include persistent cough, chest pain, and breathing difficulties. Diagnosis involves imaging, biopsy, and staging to determine the cancer's extent. Treatment options depend on the stage but may...
-
Product Insights
Non-Small Cell Lung Carcinoma - Drugs In Development, 2024
Empower your strategies with our Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the...
-
Product Insights
Lung Adenocarcinoma - Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
Metastatic Lung Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Lung Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic lung cancer, also known as stage IV lung cancer, is an advanced form of lung cancer characterized by the spread of cancerous cells from the lungs to distant parts of the body. It typically occurs when cancer cells break away from the primary tumor in the lungs and travel through the bloodstream or lymphatic system to other organs or tissues,...
-
Product Insights
Squamous Non-Small Cell Lung Carcinoma - Drugs In Development, 2024
Empower your strategies with our Squamous Non-Small Cell Lung Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Analysis and Forecast to 2032
Non-Small Cell Lung Cancer (NSCLC) Report Overview In the 8MM, there were 1,097,467 diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) in 2022. The diagnosed incident cases of Non-Small Cell Lung Cancer (NSCLC) will register an AGR of more than 2% during 2022-2032. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, NSCLC can begin anywhere in the lungs when the healthy cells that make up the lining of the lungs change and grow out...
-
Thematic Analysis
Digital Marketing Trends in Non-small Cell Lung Cancer
Digital Marketing Trends in Non-small Cell Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across Non-small Cell Lung Cancer (NSCLC) patient sites in the US from October 2022 to September 2023. This was followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com. Keytruda.com was also supported by the most paid search engine optimization (SEO) at over 7,600 keywords, closely followed by Enhertu.com and Opdivo.com. Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources. The Digital...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) - Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Report Overview The total market value for the 15M, which includes both CGTs and established/traditional NSCLC therapies was $30.7 billion in 2021. A high level of unmet need in the second and third line, especially in the PD-L1-negative setting will significantly drive the uptake and usage of novel CGT thereby propelling the market growth. Non-Small Cell Lung Cancer (NSCLC)–Cell and Gene Therapies 15-Market Outlook, 2021-2031 ($ Billion) Buy the Full Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.